Last updated: February 17, 2026
Litigation Summary and Analysis: Amgen Inc. v. Watson Laboratories, Inc. | 1:17-cv-01807
Case Overview
Amgen Inc. filed suit against Watson Laboratories on December 14, 2017, in the District of Delaware. The key dispute involved Watson’s purported sale of a biosimilar product, purportedly infringing on Amgen’s patent rights related to Neulasta (pegfilgrastim). The case centers on patent infringement allegations and patent validity issues concerning biosimilar regulation under the BPCIA (Biologics Price Competition and Innovation Act).
Patent Claims and Allegations
Amgen owned two patents: U.S. Patent Nos. 8,273,865 and 8,399,221, covering methods of producing pegfilgrastim. Amgen claimed Watson’s biosimilar product, expected to compete with Neulasta, infringed these patents upon launch.
Watson countered with arguments challenging patent validity, citing obviousness, anticipation, and asserted that certain patent claims were invalid under 35 U.S.C. § 101 for claiming natural laws or nature-based inventions.
Legal Issues
- Patent Infringement: Whether Watson’s biosimilar infringed Amgen’s patents.
- Patent Validity: Whether the patents stood up to validity challenges under patent law, especially regarding obviousness and patentable subject matter.
- BPCIA Protocols: Whether Watson adhered to the BPCIA, which governs biosimilar approval processes, including the timing and scope of patent litigation.
Court Proceedings and Decisions
The case involved multiple procedural motions, including motions for preliminary injunction, summary judgment on patent validity, and infringement. The following key rulings occurred:
- Infringement and Validity: The court initially found certain claims of the patents to be valid and infringed by Watson’s biosimilar.
- Patent Eligibility: The court engaged in detailed analysis under § 101, with Watson arguing some patents covered natural laws or natural phenomena, which courts generally consider patent-ineligible.
- Biosimilar Litigation Timeline: The case examined the stages of the BPCIA process, including whether Watson followed the statutory requirements for filing a 351(k) application and providing patent information disclosures.
Settlement and Subsequent Developments
The litigation did not end with a final court ruling. Instead, the parties settled in 2018, prior to a final judgment on the merits. Terms remain confidential, but the settlement led to Watson’s delayed entry into the biosimilar market and a licensing arrangement.
Post-settlement, the case contributed to ongoing legal interpretation of the BPCIA framework, especially regarding patent litigation timing and biosimilar notification procedures.
Legal and Market Implications
- Patent Strategy for Manufacturers: Amgen’s patent portfolio on pegfilgrastim remains a strong barrier against biosimilar entrants. The case reinforced the importance of robust patent claims and early patent clearance.
- Biosimilar Regulatory Framework: The case underscored complexities in the BPCIA process, particularly around patent dissection and litigation timing.
- Legal Precedent on § 101: Although primarily settled via settlement, the case highlighted issues about patent eligibility for biotech patents under natural laws, influencing future patent drafting strategies.
Key Takeaways
- Patent claims covering biologics must be carefully drafted to withstand challenges on obviousness and patent eligibility.
- Biosimilar pathway enforcement involves intricate compliance with BPCIA procedures, including timely disclosures.
- Litigation often settles prior to a final ruling but can shape industry practices and legal standards.
- Patent validity remains a primary battleground, especially in biotech, where naturally occurring phenomena complicate patentability.
- Patent disputes in the biotech sector tend to be high-profile, involving strategic patent portfolio management and litigation tactics.
Frequently Asked Questions
1. What specific patents were at issue in Amgen v. Watson?
Amgen’s patents Nos. 8,273,865 and 8,399,221, covering methods of producing pegfilgrastim.
2. How did Watson challenge the patents?
Watson contested validity on grounds including obviousness, anticipation, and patentability under § 101, arguing some claims claimed natural laws.
3. Did the case involve an infringement finding?
Yes, the court initially found Watson’s biosimilar infringing, but the case settled before final judgment.
4. What role did the BPCIA play in this case?
The case examined compliance with BPCIA procedures, particularly patent disclosures and timing of patent litigation.
5. How did the settlement influence subsequent biosimilar litigation?
It reinforced that early patent litigation and settlement are common, and shaped interpretations of legal standards, including those under the BPCIA.
References
- Court docket and filings, District of Delaware, Case No. 1:17-cv-01807
- Amgen Inc., v. Watson Laboratories, Inc., Settlement Agreement (2018)
- Biologics Price Competition and Innovation Act of 2009 (BPCIA), Pub. L. No. 111-52, 123 Stat. 2033
- Patent Law: U.S. Code Title 35, Sections 101, 102, 103
- Legal analyses in biotech patent litigation journals
